首页> 美国卫生研究院文献>Journal of Enzyme Inhibition and Medicinal Chemistry >Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms
【2h】

Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms

机译:开放糖精基仲磺酰胺可作为与癌症相关的碳酸酐酶IX和XII亚型的有效和选择性抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A large number of novel secondary sulfonamides based on the open saccharin scaffold were synthesized and evaluated as selective inhibitors of four different isoforms of human carbonic anhydrase (hCA I, II, IX and XII, EC 4.2.1.1). They were obtained by reductive ring opening of the newly synthesized N-alkylated saccharin derivatives and were shown to be inactive against the two cytosolic off-target hCA I and II (Kis > 10 µM). Interestingly, these compounds inhibited hCA IX in the low nanomolar range with Kis ranging between 20 and 298 nM and were extremely potent inhibitors of hCA XII isoenzyme (Kis ranging between 4.3 and 432 nM). Since hCA IX and XII are the cancer-related isoforms recently validated as drug targets, these results represent an important goal in the development of new anticancer candidates. Finally, a computational approach has been performed to better correlate the biological data to the binding mode of these inhibitors.
机译:合成了大量基于开放糖精支架的新型仲磺酰胺,并将其评估为人类碳酸酐酶的四种不同同工型的选择性抑制剂(hCA I,II,IX和XII,EC 4.2.1.1)。它们是通过新合成的N-烷基化糖精衍生物的还原开环而获得的,并且显示出对两种胞质脱靶hCA I和II均无活性(Kis> 10 µM)。有趣的是,这些化合物在低纳摩尔范围内抑制hCA IX,其Kis在20至298 nM之间,并且是hCA XII同工酶的极强抑制剂(Kis在4.3至432 nM之间)。由于hCA IX和XII是最近被证实可作为药物靶标的癌症相关同种型,因此这些结果代表了开发新的抗癌候选药物的重要目标。最后,已经执行了一种计算方法以更好地将生物学数据与这些抑制剂的结合模式相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号